Talk:Luteolin

Contradiction with Alpha-glucosidase

The Alpha-glucosidase page (under the section titled disease relevance) suggests that Luteolin is an Alpha-glucosidase inhibitor, which should slow the conversion of complex carbohydrates into simple monosaccharides which can be absorbed in the small intestine. To me, this suggests that Luteolin inhibits carbohydrate metabolism, however, in the introduction on this page, is it said to promote carbohydrate metabolism. Which statement is correct? I am not a biochemist, but these two pages seem to contradict one another. Elesueur (talk) 05:10, 22 May 2012 (UTC)

Structure

The structure of luteolin is wrong --Kupirijo 07:28, 27 November 2006 (UTC)

It is currently correct. --Ed (Edgar181) 01:17, 14 March 2007 (UTC)

Bot report : Found duplicate references !

In the last revision I edited, I found duplicate named references, i.e. references sharing the same name, but not having the same content. Please check them, as I am not able to fix them automatically :)

• "MannSecondaryMetabolism" :
  • {{cite book | last = Mann | first = John | title = Secondary Metabolism (2nd. ed.) | publisher = [[Oxford University Press]] | date = 1992 | location = Oxford, UK | pages = 279-280 | isbn = 0-19-855529-6}}
  • {{cite book | last = Mann }}

DumZiBoT (talk) 20:29, 10 August 2008 (UTC)

_________________________________________________________________

Side Effects

Luteolin is a PDE1 through PDE5 inhibitor

But mostly luteolin is a PDE4 Inhibitor see: Phosphodiesterase inhibitor

Luteolin side effects might include erection and have difficulty to breath or swallow.
Taking Luteolin you might possibly choke to death if you have Asthma.

Please See Study and Reference I cited:

Eur J Pharmacol. 2009 Oct 22. [Epub ahead of print] Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [(3)H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia. Yu MC, Chen JH, Lai CY, Han CY, Ko WC.

Department of Internal Medicine, Taipei Municipal Wan-Fang Hospital, Taiwan. The aim of the present study was to investigate the mode of action of luteolin on phisphodiesterase (PDE) 1-5, and the possible adverse effects, such as nausea, vomiting, and gastric hypersecretion, determined by replacing [(3)H]-rolipram binding and reversing xylazine/ketamine-induced anesthesia. The reversing effect was reported to occur through a presynaptic alpha(2)-adrenoceptor inhibition and trigger vomiting in ferrets. In contrast, clonidine, an alpha(2)-adrenoceptor agonist, prevented emesis induced by PDE4 inhibitors in ferrets. According to the Lineweaver-Burk analysis, luteolin (3-30muM) competitively inhibited PDE1-5 activities, with K(i) values of 15.0, 6.4, 13.9, 11.1, and 9.5muM, respectively, which did not significantly differ from each other. The equilibrium dissociation constant (K(d)) and maximal density (B(max)) for [(3)H]-rolipram binding at high-affinity rolipram binding sites of guinea pig brain cell membranes were 10.1nM and 3.7pmol/g of tissue, respectively. The EC(50) (PDE4(H)) values of luteolin and Ro 20-1724, a selective PDE4 inhibitor, for displacing 2nM [(3)H]-rolipram binding were 11.2muM and 45.6nM, respectively. The therapeutic (PDE4(H)/PDE4(L)) ratios of luteolin and Ro 20-1724 were calculated to be 0.6, and 0.004, respectively. Both luteolin (10-30mumol/kg, s.c.) and Ro 20-1724 (0.1-1mumol/kg, s.c.) significantly reversed the xylazine/ketamine-induced anesthesia in mice. Although luteolin non-selectively and competitively inhibited PDE1-5, only PDE4 inhibition contributed to a reversing effect. In conclusion, because of the low therapeutic (PDE4(H)/PDE4(L)) ratio of luteolin, the gastrointestinal adverse effects such as nausea, vomiting and gastric hypersecretion should be carefully monitored, whenever luteolin is used for treating allergies, asthma or chronic obstructive pulmonary disease.

PMID: 19853596

http://www.ncbi.nlm.nih.gov/pubmed/19853596

Bixbyte (talk) 23:13, 6 November 2009 (UTC)Bixbyte

"Luteolin side effects might include erection and have difficulty to breath or swallow".

You call erection a side effect? Most men want more erections. Probably requires a huge dose? 91.155.24.127 (talk) 17:18, 23 April 2017 (UTC)

____________________________________________________________

Clinical trials - antinflammatory, microglia modulator

Could mention the clinical trials [1] and the stated reasoning behind them ? - Rod57 (talk) 13:46, 27 January 2017 (UTC)

Why do plants make it, what effect in animals that eat those plants

What is written about its function in plants, and its absorption, digestion and biochemistry in mammals ? - Rod57 (talk) 13:49, 27 January 2017 (UTC)

Pharmacology

There's quite a bit of research on the pharmacology of luteoin, and related quercetin, in humans. Of particular interest to the public, luteolin is a potent endocrine disruptor. See: https://pubmed.ncbi.nlm.nih.gov/23836117/ Ccroberts @ 22:48, 17 December 2023 (UTC)

Hi, Ccroberts! The policy is to use reviews and not primary sources. Looks like your cited article is not a review but a primary source, which are not considered strong enough for Wikipedia in terms of the reliability of their information. Cheers, --CopperKettle (talk) 09:02, 18 December 2023 (UTC)

The review literature on luteolin is plainly weak and in unreliable journals. It would be hard to justify why a section on pharmacology would be informative for the general encyclopedia user. Zefr (talk) 15:12, 18 December 2023 (UTC)